CEMP Cempra Inc.

+0.03  (1%)
Previous Close 2.30
Open 2.25
Price To book 0.80
Market Cap 122084078
Shares 52,509,281
Volume 510,161
Short Ratio 2.35
Av. Daily Volume 856,054

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due by the end of 2017.
Taksta - Fusidic acid
Refractory infections in bones and joints
CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Noted February 28, 2017 that development has been suspended due to lack of efficacy.
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged. Finally noted February 28, 2017 that data did not demonstrate non-inferiority (NI) to standard of care.
Uncomplicated urogenital gonococcal infections
Phase 3 data released February 24, 2017 - endpoints met. Second Phase 3 trial to be initiated.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.

Latest News

  1. As merger closes, Cempra now trading as Melinta
  2. Cempra, Inc. :CEMP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
  3. How Cempra’s shareholder vote on Melinta merger shook out
  4. Cempra Announces Preliminary Results of 2017 Stockholder Vote 
  5. Is It The Right Time To Buy Cempra Inc (CEMP)?
  6. New CEO in place for Cempra, Melinta combination
  7. Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization
  8. Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company
  9. What You Must Know About Cempra Inc’s (CEMP) Financial Strength
  10. ETFs with exposure to Cempra, Inc. : October 30, 2017
  11. 3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis
  12. Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities
  13. Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
  14. Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
  15. Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger
  16. ETFs with exposure to Cempra, Inc. : September 28, 2017
  17. Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios
  18. Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections
  19. SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP